Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2008-09-02
2010-06-22
Woodward, Cherie M (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S153100, C424S173100, C435S006120, C435S029000
Reexamination Certificate
active
07740848
ABSTRACT:
Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23.
REFERENCES:
patent: 6914128 (2005-07-01), Salfeld et al.
patent: 7090847 (2006-08-01), Oppmann et al.
patent: 7183057 (2007-02-01), Benson
patent: 7247711 (2007-07-01), Benson et al.
patent: 7332156 (2008-02-01), Bowman et al.
patent: 7427402 (2008-09-01), Kastelein et al.
patent: 7501427 (2009-03-01), Wallace et al.
patent: 7575741 (2009-08-01), Bowman et al.
patent: 2003/0083231 (2003-05-01), Ahlem et al.
patent: 2004/0213761 (2004-10-01), Bowman et al.
patent: WO 99/60127 (1999-11-01), None
patent: WO 00/55204 (2000-09-01), None
patent: WO 01/46420 (2001-06-01), None
patent: WO 01/85790 (2001-11-01), None
patent: WO 02/078729 (2002-10-01), None
patent: WO 02/102411 (2002-12-01), None
patent: WO 2004/042009 (2004-05-01), None
patent: WO 2004/060291 (2004-07-01), None
patent: WO 2005/010044 (2005-02-01), None
Aggarwal and Gurney (2002)J. Leukocyte Biology71:1-8 “IL-17: prototype member of an emerging cytokine family”.
Aggarwal, et al. (2003)J. Biol. Chem. 278:1910-1914 Interleukin-23 Promotes a Distince CD4 T Cell Activation State Characerized by the Production of Interleukin-17.
Blumberg et al. (2001)Cell104:9-19 “Interleukin 20: Discovery, Receptor Identification, and Role in Epidermal Function”.
Fossiez, et al. (1996)J. Exp. Med. 183:2593-2603 “T Cell Interleukin-17 Induces Stromal Cells to Produce Proinflammatory and Hamatopoietic Cytokines”.
Ghoreschi et al (2003)Nat Med9:40-46 “Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease”.
Griffiths et al. (1991)Br. J. Dermatol. 124(6):519-526 “Modulation of leucocyte adhesion molecules, a T-cell chemotaxin (IL-8) and a regulatory cytokine (TNF-alpha) in allergic contact dermatitis (rhus dermatitis)”.
Gudjonsson et al. (2004)Clin. Exp. Immunol. 135:1-8, Review “Immunopathogenic mechanisms in psoriasis”.
Juengst (2003)BMJ326(7404):1410-1411 “What next for human gene therapy? Gene transfer often has multiple and unpredictable effects on cells”.
Kawaguchi, et al. (2001)J. Immunol. 167:4430-4435 “Identification of a Novel Cytokine, ML-1, and Its Expression in Subjects with Asthma”.
Kawaguchi, et al. (2004)J. Allergy Clin. lmmunol. 114:1265-1273 “IL-17 cytokine family”.
Kennedy, et al. (1996)J. Interferon Cytokine Res. 16:611-617 “Mouse IL-17: a cytokine preferentially expressed by alpha beta TCR + CD4-CD8-T cells”.
Kurasawa et al. (2000)Arth&Rheum. 43(11):2455-2463 “Increased Interleukin-17 Production in Patients with Systemic Sclerosis”.
Lee et al, (2004)J Exp Med199:125-130 “Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vularis”.
Liao et al, (2002)J Immunol169:4288-4297 “IL-19 Induces Production of IL-6 and TNF-α”.
Liao et al (2004)J Immunol. 173:6712-6718 “IL-19 Induced Th2 Cytokines and Was Up-Regulated in Asthma Patients”.
Nagalakshmi et al, (2004)Int Immunopharmacol4:577-592 “Expression patterns of IL-10 ligand and receptor gene families provide leads for biological characterization”.
Oppmann, et al. (2000)Immunity13:715-725 “Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12”.
Parrish-Novak (2002),J Biol Chem277: 47517-47523 “Interleukins 19, 20, and 24 Signal through Two Distinct Receptor Complexes”.
Rømer et al (2003)J Invest Dermatol6:1306-1311 “Epidermal Overexpression of Interleukin-19 and -20 mRNA in Psoriatic Skin Disappears After Short-Term Treatment with Cyclosporine A or Calcipotriol”.
Rouvier, et al. (1993)J. Immunol. 150:5445-5456 “CTLA-8, Clones from an Activated T Cell, Bearing AU-Rich Messenger RNA Instability Sequences, and Homologous to a Herpesvirus Saimiri Gene”.
Starnes et al. (2001)J. Immunol. 167(8):4137-4140 “Cutting Edge: IL-17F, a novel cytokine selectively expressed in activated C cells and Monocytes, regulates angiogenesis and endothelial cell cytokine production”.
Teunissen et al. (1998)J. Invest. Derm. 111(4):645-649 “Interleukin0-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes”.
Thompson, et al. (2003)Eds. The Cytokine Handbook, Fourth Edition, vol. 1. Academic Press, San Diego, pp. 383-385.
Wang et al (2002)J Biol Chem277:7341-7347; “Interleukin 24 (MDA-7/MOB-5) Signals through Two Heterodimeric Receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2”.
Wiekowski, et al. (2001)J. Immunol. 166:7563-7570 “Ubiquitous Transgenic Expression of the IL-23 Subunit p19 Induces Multiorgan Inflammation, Runting, Infertility, and Premature Death”.
Witowski et al (2004)Cellular and Molecular Life Sciences61(5):567-579 “Interleukin-17: a mediator of inflammatory responses”.
Yao, et al. (1995) Immunity 3:811-821; “Herpesvirus Saimiri Encodes a New Cytokine, IL-17, Which Binds to a Novel Cytokine Receptor”.
Chan Jason R.
Kastelein Robert A.
McClanahan Terrill K.
Murphy Erin
Bellomy Gregory R.
Schering Corporation
Woodward Cherie M
LandOfFree
Method of treatment of skin inflammation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment of skin inflammation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment of skin inflammation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4186747